About: Ginkgotoxin is a research topic. Over the lifetime, 32 publications have been published within this topic receiving 612 citations. The topic is also known as: 4'-O-methylpyridoxine & 5-(hydroxymethyl)-4-(methoxymethyl)-2-methylpyridin-3-ol.
TL;DR: The present paper summarizes recent experiences with G. biloba and its derived products and explains why their restricted use is recommended.
Abstract: Products prepared from Ginkgo biloba are top-selling phytopharmaceuticals especially in Europe and major botanical dietary supplements in the United States. In European medicine, G. biloba medications are used to improve memory, to treat neuronal disorders such as tinnitus or intermittent claudication, and to improve brain metabolism and peripheral blood flow. The whole array of indications is reflected by a number of defined natural product constituents in G. biloba. The most well-known ones are flavonoids and terpene lactones, but they also include allergenic and toxic compounds such as ginkgotoxin (1). Consequently, there are reports attributing beneficial as well as adverse effects to G. biloba products. The present paper summarizes recent experiences with G. biloba and its derived products and explains why their restricted use is recommended.
TL;DR: The amount of the toxin in Ginkgo biloba leaves is likely to be too low to exert a detrimental effect after administration of the medication or ingestion of food, and the toxin is even detectable in homoeopathic preparations.
Abstract: 4'-O-methylpyridoxine (ginkgotoxin) is a neurotoxic antivitamin B6 which occurs in Ginkgo biloba L. seeds. Contrary to a previous report by Wada et al., the toxin was also detected in Ginkgo biloba leaves. The leaves are a source of extracts (e.g. EGb761) employed in the preparation of Ginkgo medications. Consequently the toxin is also present in Ginkgo medications and is even detectable in homoeopathic preparations. The toxin occurs also in boiled Japanese Ginkgo food. However, the amount of the toxin is likely to be too low to exert a detrimental effect after administration of the medication or ingestion of food.
TL;DR: The results of tracer experiments with radioactive and stable isotopes, feeding experiments, and molecular biological studies led to the prediction that 4-hydroxy-L-threonine and 1-deoxy-D-xylulose are precursors which are assembled to yield the carbon-nitrogen skeleton of vitamin B6.
Abstract: In spite of the rather simple structure of pyridoxal 5'-phosphate (I), a member of the vitamin B6 group, the elucidation of its de novo biosynthesis remained largely unexplored until recently. Experiments designed to investigate the formation of the vitamin B6 pyridine nucleus mainly concentrated on Escherichia coli. The results of tracer experiments with radioactive and stable isotopes, feeding experiments, and molecular biological studies led to the prediction that 4-hydroxy-L-threonine (VIII, R = H) and 1-deoxy-D-xylulose (VII, R = H) are precursors which are assembled to yield the carbon-nitrogen skeleton of vitamin B6. At this point, the involvement of the phosphorylated forms of these precursors in this assembly seems quite clear. However, vitamin B6 biosynthesis in organisms other than E. coli remains largely unknown. Toxic derivatives of vitamin B6, such as ginkgotoxin, occurring in higher plants may be suitable targets to gain further insight into this tricky problem.
TL;DR: An antivitamin B6, 4'-methoxypyridoxine (1) was isolated from the seed of Ginkgo biloba L. (Ginkgoaceae) and is reported for the first time from natural products.
Abstract: An antivitamin B6, 4'-methoxypyridoxine (1) was isolated from the seed of Ginkgo biloba L. (Ginkgoaceae). The albumen of the seed of G. biloba L., which is called "Gin-nan or Ginkyo", is used as a crude drug in China and as food in Japan. However, in Japan, there have been about 70 reports of "Gin-nan sitotoxism." In this paper, we report that the substance responsible for this sitotoxism is 4'-methoxypyridoxine (1), which is known to have antivitamin B6 activities. This compound (1) is reported for the first time from natural products.
TL;DR: It is shown that ginkgotoxin serves as an alternate substrate for this enzyme with a lower Km value than pyridoxal, pyrIDoxamine or pyriridoxine, which leads to temporarily reduced pyrinoxal phosphate formation in’vitro and possibly also in vivo.
Abstract: Ginkgotoxin (4′-O-methylpyridoxine) occurring in the seeds and leaves of Ginkgo biloba, is an antivitamin structurally related to vitamin B6. Ingestion of ginkgotoxin triggers epileptic convulsions and other neuronal symptoms. Here we report on studies on the impact of B6 antivitamins including ginkgotoxin on recombinant homogeneous human pyridoxal kinase (EC 2.7.1.35). It is shown that ginkgotoxin serves as an alternate substrate for this enzyme with a lower Km value than pyridoxal, pyridoxamine or pyridoxine. Thus, the presence of ginkgotoxin leads to temporarily reduced pyridoxal phosphate formation in vitro and possibly also in vivo. Our observations are discussed in light of Ginkgo medications used as nootropics.